The MELD-Na score is a widely accepted method for evaluating prognosis in chronic liver disease and decompensated cirrhosis. It builds upon the original MELD score, which was initially developed to predict outcomes in patients undergoing TIPS, by adding serum sodium. Hyponatremia is a significant marker of poor outcomes in cirrhosis, particularly when linked with complications like ascites and hepatorenal syndrome.

By including sodium, MELD-Na more accurately reflects mortality risk compared to MELD alone. The score ranges from 6 to 40, with higher scores indicating higher mortality. It is central to liver transplantation allocation systems, including UNOS/OPTN in the United States, where transplant priority is determined by MELD-Na rather than MELD.

Outside of transplantation, the score provides clinicians with an objective, reproducible method to discuss prognosis, decide on hospital admission, and monitor disease progression. It has become a routine part of hepatology practice because it uses standard labs available in most hospitals, ensuring global applicability. Ultimately, MELD-Na helps identify patients at highest risk and ensures timely interventions, making it an essential tool in the management of advanced liver disease.